Compare ARDX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2014 | 2015 |
| Metric | ARDX | COLL |
|---|---|---|
| Price | $6.22 | $34.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $15.14 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 3.3M | 368.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $2,607,000.00 | ★ $780,567,000.00 |
| Revenue This Year | $37.75 | $8.01 |
| Revenue Next Year | $34.24 | N/A |
| P/E Ratio | ★ N/A | $83.63 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $3.74 | $29.19 |
| 52 Week High | $8.40 | $50.79 |
| Indicator | ARDX | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 57.43 | 55.27 |
| Support Level | $5.46 | $34.03 |
| Resistance Level | $6.23 | $35.86 |
| Average True Range (ATR) | 0.27 | 1.22 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 78.88 | 86.27 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.